Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: International Conference on Prevention & Infection Control (ICPIC 2011)

Open Access Poster presentation

Laboratory antimicrobial resistance surveillance: extend spectrum beta lactamase (ESBL) producing E. coli

S Mobasherizadeh1*, S Jalalpoor2, A Ebneshahidi3 and L Ghaedi1

  • * Corresponding author: S Mobasherizadeh

Author Affiliations

1 Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of

2 2. Islamic Azad University Shahreza Branch, Isfahan, Iran, Islamic Republic of

3 Sadi Hospital, Isfahan, Iran, Islamic Republic of

For all author emails, please log on.

BMC Proceedings 2011, 5(Suppl 6):P135  doi:10.1186/1753-6561-5-S6-P135

The electronic version of this article is the complete one and can be found online at:

Published:29 June 2011

© 2011 Mobasherizadeh et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction / objectives

This study aims to investigate the prevalence of ESBL producing E.coli in urinary tract nosocomial and community acquired infections of Isfahan selected hospitals.


The present study was performed at four tertiary care hospitals in Isfahan, Iran. During a 14 month period (Jun, 7th,2008 to July,6th ,2010).690 of E.coli isolated from urinary tract infection were studied. 425 of E.coli isolated from community acquired and 265 isolated from nosocomial urinary tract infection were evaluated. Standard microbiological methods were performed(according to CLSI 2006). In order to validate the extended-spectrum beta-lactamases (ESBLs) producing strains were used by disk diffusion method. The collected data was analyzed thorough whonet 5.6 software.


The prevalence of ESBLs producing E.coli isolated from community acquired urinary tract infection came out to be 17% and 58% for urinary tract nosocomial infection respectively(P<0.001).The antibiotic resistance rates of isolated in nosocomial and community UTIs were 94.9% and 84.4% to ampicillin.(P<0.01),59.4% and 19.7% to ceftazidime, 64.2% and 19.8% to cefotaxime, 62.5% and 12.2% to ceftizoxime 60% and 18.6% to gentamicin.(P<0.001), 17% and 8.2% to amikacin , and 40.8% to Nalidixic acid, 23.1% and 10.2% to nitrofurantoin,47.5% and 31.4% to ciprofloxacin and 84.4% and 60.1% to trimethoprim/sulfamethoxazole (p<0.005).


Establish systems for monitoring antimicrobial resistance in hospitals and the community and link these findings to resistance and disease surveillance data is fundamental to developing treatment guidelines accurately and to assessing the effectiveness of interventions appropriately.

Disclosure of interest

None declared.